Advertisement

Topics

Cellectis Company Profile

12:44 EST 11th December 2018 | BioPortfolio

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.


News Articles [39 Associated News Articles listed on BioPortfolio]

A Day After Second-Quarter Report, Cellectis Appoints New SVP and Deputy CMO

Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.

Novartis Exec Scherer Joins Cellectis as Deputy Chief Medical Officer

Stefan Scherer has been appointed senior vice president of clinical development and deputy chief medical officer of Cellectis (NASDAQ: CLLS). He comes to the French cell therapy developer from Novarti...

Cellectis bakes safety switch into CAR-T to stop runaway responses

Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.

Cellectis: Monthly Information on Share Capital and Company Voting Rights

(Article 223-16 of General Regulation of the French financial markets authority) Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS): Listing market: Euronext Growth ISIN code: FR0010425595 Dat...

Cellectis: Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO

Calyxt to host conference call on Wednesday, August 22, 2018 at 8:30 a.m. ET 7:30 a.m. CT Regulatory News: Calyxt, Inc. (NASDAQ: CLXT) and Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) announced toda...

Cellectis: Shareholders' General Meeting of June 26, 2018

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited ...

US FDA approves Cellectis’ third ‘off-the-shelf’ CAR T-cell candidate for clinical trials

Cellectisâ third gene-edited, âoff-the-shelfâ CAR T-cell candidate is set to enter clinical development after the US FDA approved an IND application for UCART22.

Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018

Regulatory News: Cellectis S.A. Annual General Meeting (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in ...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Life sciences licensing deals in the second quarter of 2018: updates and trends.

During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers and acquisitions) with a total disclosed deal value of USD 19.5 billion as part of its...

Clinical Trials [0 Results]

None

Companies [9 Associated Companies listed on BioPortfolio]

Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications ...

Cellectis Group

Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis A...

Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization. ...

Cellectis S.A.

Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery a...

Cellectis therapeutics

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applicat...

More Information about "Cellectis" on BioPortfolio

We have published hundreds of Cellectis news stories on BioPortfolio along with dozens of Cellectis Clinical Trials and PubMed Articles about Cellectis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cellectis Companies in our database. You can also find out about relevant Cellectis Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Corporate Database Quicklinks



Searches Linking to this Company Record